Thus AFP, which was first discovered 55 years ago by Tatarinov experimentally and then by Abelev clinically [13], has retained its place in HCC diagnosis and as a marker of response to therapy and for prognosis [14]. The gene discussed is AFP; the disease is hepatocellular carcinoma.